On July 29, 2016 Takeda Pharmaceutical Company Limited (TOKYO:4502) reported 1st Quarter 2016 Results Schedule your 30 min Free 1stOncology Demo!
with a Strong Start to the Year (Press release, Takeda, JUL 29, 2016, View Source [SID:1234514134]).
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Strong first quarter results and confidence in Management Guidance
• Underlying revenue grew +9.1%, driven by a +15.3% increase of Takeda’s Growth Drivers (GI, Oncology, CNS and Emerging Markets). (Reported revenue declined -2.8% to 434.0 billion yen, due to divestments and currency impacts)
• Underlying Core Earnings advanced +40.4% (reported operating profit was 152.9 billion yen, up from 49.6 billion yen in Q1, 2015)
• Underlying Core Net Profit and EPS were up +54.2% (reported EPS increased to 127 yen, from 31 yen in Q1, 2015)
Takeda’s Growth Drivers are accelerating
• GI underlying revenue advanced +35.3%, driven by ENTYVIO() and TAKECAB()
• Oncology underlying revenue grew +6.6% (+7.5% excluding VELCADE() royalties), driven by NINLARO( )and ADCETRIS()
• CNS underlying revenue of +31.5% was boosted by strong TRINTELLIX() performance
• Emerging Markets underlying revenue growth was +3.9%
All regions are growing, driven by innovative products
• Japan underlying revenue was up +9.7%, driven by TAKECAB(), AZILVA() and LOTRIGA()
• US underlying revenue growth of +14.9%, led by ENTYVIO(), NINLARO( )and TRINTELLIX()
• Europe and Canada underlying revenue grew +6.2%, reflecting ENTYVIO() and ADCETRIS()
•Emerging Markets underlying revenue was up +3.9%, reflecting growth in China (+12.6%), Russia (+9.5%) and Brazil (+1.0%)
Full-year forecast (reported base) has been maintained. R&D transformation does not affect our FY2016 guidance or dividend payment (see separate press release for more details)
Christophe Weber, President and Chief Executive Officer of Takeda, commented:
"Takeda had a strong start to FY2016, as we focus on executing our strategic roadmap. It is promising that our growth driver products are contributing strongly to each region’s underlying revenue growth, especially ENTYVIO, NINLARO, ADCETRIS, TRINTELLIX, and TAKECAB. Takeda will refocus research & development on targeted therapeutic areas – Oncology, Gastroenterology (GI) and Central Nervous System (CNS), plus Vaccines, and concentrate its R&D activities in Japan and the U.S. to build a world-leading R&D organization and pipeline. I am confident that these achievements and initiatives will result in Takeda’s sustainable future growth as a leading, global innovative pharmaceutical company."
Reported Results for
1Q (April – June) of FY2016
Reported base FY 2015 FY 2016 Growth
(billion yen) Q1 Q1 Underlying2
Revenue 446.3 434.0 -2.8% +9.1%
Core Earnings1 83.7 77.1 -7.9% +40.4%
Operating Profit 49.6 152.9 +208.6% N/A
Net Profit3 24.6 99.5 +304.9% N/A
EPS 31 yen 127 yen +306.5% N/A
Core EPS 65 yen 71 yen +8.7% +54.2%
1 Core Earnings is calculated by taking reported gross profit and deducting SG&A expenses and R&D expenses.
In addition, certain other items that are significant in value and non-recurring or non-core in nature may also be adjusted.
2 "Underlying growth", comparing two periods of financial results under a common basis, shows the real performance of the business. Takeda adopts "Underlying Growth" of revenue, Core Earnings and Core EPS as its indicators for management guidance. It excludes the impact of foreign exchange and divestments.
3 Attributable to the owners of the company
Takeda maintains full-year Management Guidance and reported base forecast for FY2016:
FY2016
Management Guidance
Underlying Revenue Mid-single digit growth (%)
Underlying Core Earnings Low- to mid-teen growth (%)
Underlying Core EPS Low- to mid-teen growth (%)
Annual Dividend per Share 180 yen
Reported
Base Forecast for FY2016
(billion yen1)
Revenue 1,720.0
R&D Expenses 325.0
Operating Profit 135.0
Net Profit 2 88.0
EPS 112 yen
1 The exchange rate assumptions for FY2016: 1 US$=110 yen, 1 euro=125 yen
2 Attributable to the owners of the company
For more details on Takeda’s FY2016 Q1 results and other financial information please visit View Source
Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and Confidence in Management Guidance
On July 29, 2016 Takeda Pharmaceutical Company Limited (TOKYO:4502) reported 1st Quarter 2016 Results
with a Strong Start to the Year (Press release, Takeda, JUL 29, 2016, View Source [SID:1234514134]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Strong first quarter results and confidence in Management Guidance
• Underlying revenue grew +9.1%, driven by a +15.3% increase of Takeda’s Growth Drivers (GI, Oncology, CNS and Emerging Markets). (Reported revenue declined -2.8% to 434.0 billion yen, due to divestments and currency impacts)
• Underlying Core Earnings advanced +40.4% (reported operating profit was 152.9 billion yen, up from 49.6 billion yen in Q1, 2015)
• Underlying Core Net Profit and EPS were up +54.2% (reported EPS increased to 127 yen, from 31 yen in Q1, 2015)
Takeda’s Growth Drivers are accelerating
• GI underlying revenue advanced +35.3%, driven by ENTYVIO() and TAKECAB()
• Oncology underlying revenue grew +6.6% (+7.5% excluding VELCADE() royalties), driven by NINLARO( )and ADCETRIS()
• CNS underlying revenue of +31.5% was boosted by strong TRINTELLIX() performance
• Emerging Markets underlying revenue growth was +3.9%
All regions are growing, driven by innovative products
• Japan underlying revenue was up +9.7%, driven by TAKECAB(), AZILVA() and LOTRIGA()
• US underlying revenue growth of +14.9%, led by ENTYVIO(), NINLARO( )and TRINTELLIX()
• Europe and Canada underlying revenue grew +6.2%, reflecting ENTYVIO() and ADCETRIS()
•Emerging Markets underlying revenue was up +3.9%, reflecting growth in China (+12.6%), Russia (+9.5%) and Brazil (+1.0%)
Full-year forecast (reported base) has been maintained. R&D transformation does not affect our FY2016 guidance or dividend payment (see separate press release for more details)
Christophe Weber, President and Chief Executive Officer of Takeda, commented:
“Takeda had a strong start to FY2016, as we focus on executing our strategic roadmap. It is promising that our growth driver products are contributing strongly to each region’s underlying revenue growth, especially ENTYVIO, NINLARO, ADCETRIS, TRINTELLIX, and TAKECAB. Takeda will refocus research & development on targeted therapeutic areas – Oncology, Gastroenterology (GI) and Central Nervous System (CNS), plus Vaccines, and concentrate its R&D activities in Japan and the U.S. to build a world-leading R&D organization and pipeline. I am confident that these achievements and initiatives will result in Takeda’s sustainable future growth as a leading, global innovative pharmaceutical company.”
Reported Results for
1Q (April – June) of FY2016
Reported base FY 2015 FY 2016 Growth
(billion yen) Q1 Q1 Underlying2
Revenue 446.3 434.0 -2.8% +9.1%
Core Earnings1 83.7 77.1 -7.9% +40.4%
Operating Profit 49.6 152.9 +208.6% N/A
Net Profit3 24.6 99.5 +304.9% N/A
EPS 31 yen 127 yen +306.5% N/A
Core EPS 65 yen 71 yen +8.7% +54.2%
1 Core Earnings is calculated by taking reported gross profit and deducting SG&A expenses and R&D expenses.
In addition, certain other items that are significant in value and non-recurring or non-core in nature may also be adjusted.
2 “Underlying growth”, comparing two periods of financial results under a common basis, shows the real performance of the business. Takeda adopts “Underlying Growth” of revenue, Core Earnings and Core EPS as its indicators for management guidance. It excludes the impact of foreign exchange and divestments.
3 Attributable to the owners of the company
Takeda maintains full-year Management Guidance and reported base forecast for FY2016:
FY2016
Management Guidance
Underlying Revenue Mid-single digit growth (%)
Underlying Core Earnings Low- to mid-teen growth (%)
Underlying Core EPS Low- to mid-teen growth (%)
Annual Dividend per Share 180 yen
Reported
Base Forecast for FY2016
(billion yen1)
Revenue 1,720.0
R&D Expenses 325.0
Operating Profit 135.0
Net Profit 2 88.0
EPS 112 yen
1 The exchange rate assumptions for FY2016: 1 US$=110 yen, 1 euro=125 yen
2 Attributable to the owners of the company
For more details on Takeda’s FY2016 Q1 results and other financial information please visit View Source
Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and Confidence in Management Guidance
On July 29, 2016 Takeda Pharmaceutical Company Limited (TOKYO:4502) reported 1st Quarter 2016 Results
with a Strong Start to the Year (Press release, Takeda, JUL 29, 2016, View Source [SID:1234514134]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Strong first quarter results and confidence in Management Guidance
• Underlying revenue grew +9.1%, driven by a +15.3% increase of Takeda’s Growth Drivers (GI, Oncology, CNS and Emerging Markets). (Reported revenue declined -2.8% to 434.0 billion yen, due to divestments and currency impacts)
• Underlying Core Earnings advanced +40.4% (reported operating profit was 152.9 billion yen, up from 49.6 billion yen in Q1, 2015)
• Underlying Core Net Profit and EPS were up +54.2% (reported EPS increased to 127 yen, from 31 yen in Q1, 2015)
Takeda’s Growth Drivers are accelerating
• GI underlying revenue advanced +35.3%, driven by ENTYVIO() and TAKECAB()
• Oncology underlying revenue grew +6.6% (+7.5% excluding VELCADE() royalties), driven by NINLARO( )and ADCETRIS()
• CNS underlying revenue of +31.5% was boosted by strong TRINTELLIX() performance
• Emerging Markets underlying revenue growth was +3.9%
All regions are growing, driven by innovative products
• Japan underlying revenue was up +9.7%, driven by TAKECAB(), AZILVA() and LOTRIGA()
• US underlying revenue growth of +14.9%, led by ENTYVIO(), NINLARO( )and TRINTELLIX()
• Europe and Canada underlying revenue grew +6.2%, reflecting ENTYVIO() and ADCETRIS()
•Emerging Markets underlying revenue was up +3.9%, reflecting growth in China (+12.6%), Russia (+9.5%) and Brazil (+1.0%)
Full-year forecast (reported base) has been maintained. R&D transformation does not affect our FY2016 guidance or dividend payment (see separate press release for more details)
Christophe Weber, President and Chief Executive Officer of Takeda, commented:
“Takeda had a strong start to FY2016, as we focus on executing our strategic roadmap. It is promising that our growth driver products are contributing strongly to each region’s underlying revenue growth, especially ENTYVIO, NINLARO, ADCETRIS, TRINTELLIX, and TAKECAB. Takeda will refocus research & development on targeted therapeutic areas – Oncology, Gastroenterology (GI) and Central Nervous System (CNS), plus Vaccines, and concentrate its R&D activities in Japan and the U.S. to build a world-leading R&D organization and pipeline. I am confident that these achievements and initiatives will result in Takeda’s sustainable future growth as a leading, global innovative pharmaceutical company.”
Reported Results for
1Q (April – June) of FY2016
Reported base FY 2015 FY 2016 Growth
(billion yen) Q1 Q1 Underlying2
Revenue 446.3 434.0 -2.8% +9.1%
Core Earnings1 83.7 77.1 -7.9% +40.4%
Operating Profit 49.6 152.9 +208.6% N/A
Net Profit3 24.6 99.5 +304.9% N/A
EPS 31 yen 127 yen +306.5% N/A
Core EPS 65 yen 71 yen +8.7% +54.2%
1 Core Earnings is calculated by taking reported gross profit and deducting SG&A expenses and R&D expenses.
In addition, certain other items that are significant in value and non-recurring or non-core in nature may also be adjusted.
2 “Underlying growth”, comparing two periods of financial results under a common basis, shows the real performance of the business. Takeda adopts “Underlying Growth” of revenue, Core Earnings and Core EPS as its indicators for management guidance. It excludes the impact of foreign exchange and divestments.
3 Attributable to the owners of the company
Takeda maintains full-year Management Guidance and reported base forecast for FY2016:
FY2016
Management Guidance
Underlying Revenue Mid-single digit growth (%)
Underlying Core Earnings Low- to mid-teen growth (%)
Underlying Core EPS Low- to mid-teen growth (%)
Annual Dividend per Share 180 yen
Reported
Base Forecast for FY2016
(billion yen1)
Revenue 1,720.0
R&D Expenses 325.0
Operating Profit 135.0
Net Profit 2 88.0
EPS 112 yen
1 The exchange rate assumptions for FY2016: 1 US$=110 yen, 1 euro=125 yen
2 Attributable to the owners of the company
For more details on Takeda’s FY2016 Q1 results and other financial information please visit View Source
Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and Confidence in Management Guidance
On July 29, 2016 Takeda Pharmaceutical Company Limited (TOKYO:4502) reported 1st Quarter 2016 Results
with a Strong Start to the Year (Press release, Takeda, JUL 29, 2016, View Source [SID:1234514134]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Strong first quarter results and confidence in Management Guidance
• Underlying revenue grew +9.1%, driven by a +15.3% increase of Takeda’s Growth Drivers (GI, Oncology, CNS and Emerging Markets). (Reported revenue declined -2.8% to 434.0 billion yen, due to divestments and currency impacts)
• Underlying Core Earnings advanced +40.4% (reported operating profit was 152.9 billion yen, up from 49.6 billion yen in Q1, 2015)
• Underlying Core Net Profit and EPS were up +54.2% (reported EPS increased to 127 yen, from 31 yen in Q1, 2015)
Takeda’s Growth Drivers are accelerating
• GI underlying revenue advanced +35.3%, driven by ENTYVIO() and TAKECAB()
• Oncology underlying revenue grew +6.6% (+7.5% excluding VELCADE() royalties), driven by NINLARO( )and ADCETRIS()
• CNS underlying revenue of +31.5% was boosted by strong TRINTELLIX() performance
• Emerging Markets underlying revenue growth was +3.9%
All regions are growing, driven by innovative products
• Japan underlying revenue was up +9.7%, driven by TAKECAB(), AZILVA() and LOTRIGA()
• US underlying revenue growth of +14.9%, led by ENTYVIO(), NINLARO( )and TRINTELLIX()
• Europe and Canada underlying revenue grew +6.2%, reflecting ENTYVIO() and ADCETRIS()
•Emerging Markets underlying revenue was up +3.9%, reflecting growth in China (+12.6%), Russia (+9.5%) and Brazil (+1.0%)
Full-year forecast (reported base) has been maintained. R&D transformation does not affect our FY2016 guidance or dividend payment (see separate press release for more details)
Christophe Weber, President and Chief Executive Officer of Takeda, commented:
“Takeda had a strong start to FY2016, as we focus on executing our strategic roadmap. It is promising that our growth driver products are contributing strongly to each region’s underlying revenue growth, especially ENTYVIO, NINLARO, ADCETRIS, TRINTELLIX, and TAKECAB. Takeda will refocus research & development on targeted therapeutic areas – Oncology, Gastroenterology (GI) and Central Nervous System (CNS), plus Vaccines, and concentrate its R&D activities in Japan and the U.S. to build a world-leading R&D organization and pipeline. I am confident that these achievements and initiatives will result in Takeda’s sustainable future growth as a leading, global innovative pharmaceutical company.”
Reported Results for
1Q (April – June) of FY2016
Reported base FY 2015 FY 2016 Growth
(billion yen) Q1 Q1 Underlying2
Revenue 446.3 434.0 -2.8% +9.1%
Core Earnings1 83.7 77.1 -7.9% +40.4%
Operating Profit 49.6 152.9 +208.6% N/A
Net Profit3 24.6 99.5 +304.9% N/A
EPS 31 yen 127 yen +306.5% N/A
Core EPS 65 yen 71 yen +8.7% +54.2%
1 Core Earnings is calculated by taking reported gross profit and deducting SG&A expenses and R&D expenses.
In addition, certain other items that are significant in value and non-recurring or non-core in nature may also be adjusted.
2 “Underlying growth”, comparing two periods of financial results under a common basis, shows the real performance of the business. Takeda adopts “Underlying Growth” of revenue, Core Earnings and Core EPS as its indicators for management guidance. It excludes the impact of foreign exchange and divestments.
3 Attributable to the owners of the company
Takeda maintains full-year Management Guidance and reported base forecast for FY2016:
FY2016
Management Guidance
Underlying Revenue Mid-single digit growth (%)
Underlying Core Earnings Low- to mid-teen growth (%)
Underlying Core EPS Low- to mid-teen growth (%)
Annual Dividend per Share 180 yen
Reported
Base Forecast for FY2016
(billion yen1)
Revenue 1,720.0
R&D Expenses 325.0
Operating Profit 135.0
Net Profit 2 88.0
EPS 112 yen
1 The exchange rate assumptions for FY2016: 1 US$=110 yen, 1 euro=125 yen
2 Attributable to the owners of the company
For more details on Takeda’s FY2016 Q1 results and other financial information please visit View Source